Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)Francesco Zappa, Miklos Pless, Oliver Gautschi et al.|Lung Cancer|2012Cited by 32
Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC studyChia‐Yu Chu, Elise Dekker, Anwar Al Hammadi et al.|World Allergy Organization Journal|2020Cited by 16
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung CancerFlorent Baty, Martin Brutsche, Sacha I. Rothschild et al.|PLoS ONE|2013Cited by 11